<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542632</url>
  </required_header>
  <id_info>
    <org_study_id>INV-DEN-104</org_study_id>
    <secondary_id>U1111-1177-8166</secondary_id>
    <nct_id>NCT01542632</nct_id>
  </id_info>
  <brief_title>A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 study to compare the safety, tolerability and immunogenicity of different dose
      schedules of subcutaneously (SC) administered dengue vaccine in healthy adults and to compare
      the immunogenicity of different dose schedules of the vaccine.

      Blood samples were obtained for safety labs on Days 0, 7, 14, 90, 97, 104 and measurement of
      viremia at baseline [during the screening period or on day of vaccination (Day 0)], and then
      on Days 7, 9, 11, 14, 17, 21, 90, 97, and 104. Blood samples for measurement of dengue
      neutralizing antibodies in serum were obtained at baseline [during the screening period or on
      day of vaccination (Day 0)], then on Days 30, 90 and 120.

      The entire duration for each individual subjects participation was approximately 5 months
      including recruitment and collection of data for primary outcomes (through Day 120).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">January 10, 2014</completion_date>
  <primary_completion_date type="Actual">January 1, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported</measure>
    <time_frame>Day 0 to Day 104</time_frame>
    <description>Erythema and Edema Were Graded Per The FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Where Grade 0=none to Grade 4=Severe. Pain and Itching were graded using Common Terminology Criteria for Adverse Events (CTCAE) 4.03 where Grade 0=no pain or itching to Grade 4= Life-threatening/severe. Only those score categories for which there was at least 1 participant are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least 1 Adverse Event Following Either Vaccine Dose</measure>
    <time_frame>For 30 days after each dose (Up to Day 120)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least 1 Adverse Events Related to TDV Following Either Vaccine Dose</measure>
    <time_frame>For 30 days after each dose (Up to Day 120)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. Some AEs are automatically considered related because of temporal relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Seroconversion to Each of Four Dengue Serotypes</measure>
    <time_frame>Up to 30 days after the last immunization (Up to Day 120)</time_frame>
    <description>Rate of seroconversion was defined as the percentage of participants with Plaque Reduction Neutralization Test titer resulting in 50 % reduction in Plagues (PRNT50) titer ≥ 10 for participants seronegative at Baseline or a greater than four-fold increase in PRNT50 for participants seropositive at Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serotype-Specific TDV Viral RNA Detected After First and Second Vaccinations</measure>
    <time_frame>various timepoints up to 30 days after each dose (Up to Day 120)</time_frame>
    <description>Serotype-Specific TDV Viral RNA was assessed for the four dengue serotypes: Dengue-1, Dengue-2, Dengue-3 and Dengue-4 . Only those serotypes and time-points where at least 1 participant had Serotype-Specific TDV Viral RNA Detected is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes</measure>
    <time_frame>Days 30, 90 and 120 after 1st vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Takeda's Tetravalent Dengue Vaccine Candidate (TDV)</intervention_name>
    <description>TDV subcutaneous injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV New Formulation</intervention_name>
    <description>TDV New Formulation subcutaneous injection</description>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New Formulation Placebo</intervention_name>
    <description>New Formulation placebo subcutaneous injection</description>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 18 years and ≤ 45 years old at time of screening

          2. In good health as determined by medical history, physical examination including height
             and weight

          3. Normal clinical safety laboratory examinations [Sodium (Na), Potassium (K), Glucose,
             Blood Urea Nitrogen (BUN), creatinine, Alanine aminotransferase (ALT), Aspartate
             aminotransferase (AST), total bilirubin, White Blood Cell (WBC), neutrophil count,
             hemoglobin, platelets, Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and
             urinalysis (by dipstick)].

          4. Weight: Body Mass Index (BMI) ≤32

          5. Blood tests negative for antibodies to Human Immuno-virus (HIV-1), Hepatitis C, and
             Hepatitis B surface antigen

        Exclusion Criteria:

          1. Any condition which would limit the subject's ability to complete the study in the
             opinion of the Investigator

          2. Clinically significant ECG findings

          3. History of any significant dermatologic disease in the last 6 months,

          4. History of diabetes mellitus

          5. History of recurring headaches or migraines (more frequent than once per week) or on
             prescription medication for treatment of recurring headaches or migraines

          6. Hypersensitivity to any vaccine

          7. Receipt of any vaccine in the 4 weeks preceding the first vaccination

          8. Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in
             this study

          9. Known history of Japanese Encephalitis Virus (JEV) and/or Yellow Fever (YF)

         10. Previous vaccination (in a clinical trial or with an approved product) against
             flaviviruses including dengue, yellow fever (YF) and Japanese Encephalitis (JE)

         11. Seropositivity to dengue or West Nile (WN) virus

         12. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months

         13. Use within the previous 6 months of systemic corticosteroids therapy (at a dose of at
             least 0.5 mg/kg/day). Topical prednisone is not permitted if currently in use or
             within the last 3 months. Note, inhaled prednisone (or equivalent) is allowed

         14. Use of any non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or
             antihistamines for the 3 days immediately prior to each vaccination

         15. Use of any prescription or over the counter medications (besides those specifically
             mentioned above or those required for medical management of concurrent diseases) 7
             days before the first vaccination (Day 0)

         16. Positive urine screen for cocaine, amphetamines, opiates, or cannabinoids

         17. Donation of blood 6 weeks before the first dose(s) (Day 0) until 30 days after the
             dose on day 90

         18. Females who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inviragen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center of the Rockies</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <results_first_submitted>December 31, 2014</results_first_submitted>
  <results_first_submitted_qc>December 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2015</results_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety and immunogenicity of dengue vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 3 investigative sites in the United States from 23 January 2012 to 10 January 2014.</recruitment_details>
      <pre_assignment_details>Participants were enrolled in 1 of 6 treatment groups (GRP). GRP1: 1 dose TDV on Day 0 and 90, GRP2: 2 doses of TDV on Day 0, GRP3: 2 Doses of TDV on Day 0 and 1 dose of TDV on Day 90, GRP4: 1 Dose of TDV New Formula on Day 0 and 90, GRP5: 2 doses of TDV New Formula on Day 0 and 90 and GRP6: 1/10 dose of TDV on Day 0 and 90.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (D0:TDV,P D90:TDV)</title>
          <description>Takeda’s Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (D0:TDV,TDV D90:P)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="P4">
          <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
          <description>TDV new formulation(TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="P5">
          <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
          <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="P6">
          <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
          <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor/Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (D0:TDV,P D90:TDV)</title>
          <description>Takeda’s Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (DO:TDV,TDV D90:P)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="B4">
          <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
          <description>TDV new formulation(TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="B5">
          <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
          <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="B6">
          <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
          <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="21"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="5.74"/>
                    <measurement group_id="B2" value="28.2" spread="6.36"/>
                    <measurement group_id="B3" value="29.2" spread="6.40"/>
                    <measurement group_id="B4" value="30.0" spread="6.67"/>
                    <measurement group_id="B5" value="30.3" spread="7.95"/>
                    <measurement group_id="B6" value="32.5" spread="6.04"/>
                    <measurement group_id="B7" value="30.0" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic Or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="11.66"/>
                    <measurement group_id="B2" value="75.9" spread="13.22"/>
                    <measurement group_id="B3" value="76.7" spread="15.76"/>
                    <measurement group_id="B4" value="80.8" spread="14.12"/>
                    <measurement group_id="B5" value="77.3" spread="14.91"/>
                    <measurement group_id="B6" value="81.7" spread="16.02"/>
                    <measurement group_id="B7" value="77.5" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.71" spread="0.092"/>
                    <measurement group_id="B2" value="1.71" spread="0.084"/>
                    <measurement group_id="B3" value="1.70" spread="0.108"/>
                    <measurement group_id="B4" value="1.76" spread="0.105"/>
                    <measurement group_id="B5" value="1.73" spread="0.099"/>
                    <measurement group_id="B6" value="1.75" spread="0.104"/>
                    <measurement group_id="B7" value="1.72" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.81" spread="2.423"/>
                    <measurement group_id="B2" value="25.97" spread="3.314"/>
                    <measurement group_id="B3" value="26.50" spread="3.735"/>
                    <measurement group_id="B4" value="26.09" spread="3.202"/>
                    <measurement group_id="B5" value="25.81" spread="3.712"/>
                    <measurement group_id="B6" value="26.35" spread="3.517"/>
                    <measurement group_id="B7" value="25.91" spread="3.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported</title>
        <description>Erythema and Edema Were Graded Per The FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Where Grade 0=none to Grade 4=Severe. Pain and Itching were graded using Common Terminology Criteria for Adverse Events (CTCAE) 4.03 where Grade 0=no pain or itching to Grade 4= Life-threatening/severe. Only those score categories for which there was at least 1 participant are reported.</description>
        <time_frame>Day 0 to Day 104</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takeda’s Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 1. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported</title>
          <description>Erythema and Edema Were Graded Per The FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Where Grade 0=none to Grade 4=Severe. Pain and Itching were graded using Common Terminology Criteria for Adverse Events (CTCAE) 4.03 where Grade 0=no pain or itching to Grade 4= Life-threatening/severe. Only those score categories for which there was at least 1 participant are reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Edema=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serotype-Specific TDV Viral RNA Detected After First and Second Vaccinations</title>
        <description>Serotype-Specific TDV Viral RNA was assessed for the four dengue serotypes: Dengue-1, Dengue-2, Dengue-3 and Dengue-4 . Only those serotypes and time-points where at least 1 participant had Serotype-Specific TDV Viral RNA Detected is reported.</description>
        <time_frame>various timepoints up to 30 days after each dose (Up to Day 120)</time_frame>
        <population>Full Analysis Set included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takedas Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serotype-Specific TDV Viral RNA Detected After First and Second Vaccinations</title>
          <description>Serotype-Specific TDV Viral RNA was assessed for the four dengue serotypes: Dengue-1, Dengue-2, Dengue-3 and Dengue-4 . Only those serotypes and time-points where at least 1 participant had Serotype-Specific TDV Viral RNA Detected is reported.</description>
          <population>Full Analysis Set included all enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 Dengue-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 Dengue-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 Dengue-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17 Dengue-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Dengue-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 Dengue-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 1 Adverse Event Following Either Vaccine Dose</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.</description>
        <time_frame>For 30 days after each dose (Up to Day 120)</time_frame>
        <population>Safety Population included all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takedas Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 1 Adverse Event Following Either Vaccine Dose</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.</description>
          <population>Safety Population included all enrolled participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 1 Adverse Events Related to TDV Following Either Vaccine Dose</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. Some AEs are automatically considered related because of temporal relationship to vaccination.</description>
        <time_frame>For 30 days after each dose (Up to Day 120)</time_frame>
        <population>Safety Population included all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takedas Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 1 Adverse Events Related to TDV Following Either Vaccine Dose</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. Some AEs are automatically considered related because of temporal relationship to vaccination.</description>
          <population>Safety Population included all enrolled participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes</title>
        <time_frame>Days 30, 90 and 120 after 1st vaccination</time_frame>
        <population>Participants from the Full Analysis, all enrolled participants, with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takedas Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDV,P D90:TDV,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes</title>
          <population>Participants from the Full Analysis, all enrolled participants, with data available for analysis at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30 Dengue-1 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.6" spread="2.28"/>
                    <measurement group_id="O2" value="473.6" spread="2.60"/>
                    <measurement group_id="O3" value="370.1" spread="3.87"/>
                    <measurement group_id="O4" value="45.6" spread="3.97"/>
                    <measurement group_id="O5" value="69.1" spread="5.51"/>
                    <measurement group_id="O6" value="391.4" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Dengue-2 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6411.9" spread="7.83"/>
                    <measurement group_id="O2" value="4843.3" spread="3.42"/>
                    <measurement group_id="O3" value="6274.1" spread="3.57"/>
                    <measurement group_id="O4" value="4953.8" spread="3.01"/>
                    <measurement group_id="O5" value="5419.6" spread="3.06"/>
                    <measurement group_id="O6" value="7315.3" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Dengue-3 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="5.78"/>
                    <measurement group_id="O2" value="151.0" spread="4.12"/>
                    <measurement group_id="O3" value="70.3" spread="6.10"/>
                    <measurement group_id="O4" value="47.2" spread="5.69"/>
                    <measurement group_id="O5" value="62.0" spread="6.19"/>
                    <measurement group_id="O6" value="37.4" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 Dengue-4 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.20"/>
                    <measurement group_id="O2" value="19.4" spread="4.65"/>
                    <measurement group_id="O3" value="11.6" spread="5.00"/>
                    <measurement group_id="O4" value="45.6" spread="5.13"/>
                    <measurement group_id="O5" value="21.5" spread="5.89"/>
                    <measurement group_id="O6" value="17.4" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 Dengue-1 (n=25, 24, 23, 20, 18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.6" spread="4.26"/>
                    <measurement group_id="O2" value="130.7" spread="2.75"/>
                    <measurement group_id="O3" value="142.2" spread="6.16"/>
                    <measurement group_id="O4" value="27.3" spread="3.11"/>
                    <measurement group_id="O5" value="37.0" spread="5.91"/>
                    <measurement group_id="O6" value="127.6" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 Dengue-2 (n=25, 24, 23, 20, 18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1597.9" spread="2.81"/>
                    <measurement group_id="O2" value="1758.7" spread="3.29"/>
                    <measurement group_id="O3" value="1814.4" spread="3.13"/>
                    <measurement group_id="O4" value="1383.1" spread="2.82"/>
                    <measurement group_id="O5" value="1288.7" spread="3.14"/>
                    <measurement group_id="O6" value="1756.5" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 Dengue-3 (n=25, 24, 23, 20, 18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="4.10"/>
                    <measurement group_id="O2" value="44.9" spread="4.04"/>
                    <measurement group_id="O3" value="28.7" spread="5.38"/>
                    <measurement group_id="O4" value="20.0" spread="4.17"/>
                    <measurement group_id="O5" value="27.7" spread="4.68"/>
                    <measurement group_id="O6" value="22.6" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 Dengue-4 (n=25, 24, 23, 20, 18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.76"/>
                    <measurement group_id="O2" value="10.3" spread="3.44"/>
                    <measurement group_id="O3" value="9.4" spread="3.62"/>
                    <measurement group_id="O4" value="13.7" spread="3.60"/>
                    <measurement group_id="O5" value="11.2" spread="3.62"/>
                    <measurement group_id="O6" value="13.5" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 Dengue-1 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.2" spread="3.55"/>
                    <measurement group_id="O2" value="136.5" spread="3.88"/>
                    <measurement group_id="O3" value="216.3" spread="6.23"/>
                    <measurement group_id="O4" value="38.6" spread="2.70"/>
                    <measurement group_id="O5" value="65.4" spread="5.00"/>
                    <measurement group_id="O6" value="179.6" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 Dengue-2 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1597.9" spread="2.27"/>
                    <measurement group_id="O2" value="1478.9" spread="2.72"/>
                    <measurement group_id="O3" value="1893.9" spread="2.89"/>
                    <measurement group_id="O4" value="1631.8" spread="3.49"/>
                    <measurement group_id="O5" value="1295.5" spread="3.22"/>
                    <measurement group_id="O6" value="1356.1" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 Dengue-3 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="2.28"/>
                    <measurement group_id="O2" value="42.4" spread="3.70"/>
                    <measurement group_id="O3" value="56.6" spread="4.43"/>
                    <measurement group_id="O4" value="30.5" spread="3.36"/>
                    <measurement group_id="O5" value="51.2" spread="3.00"/>
                    <measurement group_id="O6" value="25.9" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120 Dengue-4 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="2.50"/>
                    <measurement group_id="O2" value="8.9" spread="2.70"/>
                    <measurement group_id="O3" value="12.0" spread="3.58"/>
                    <measurement group_id="O4" value="23.2" spread="3.52"/>
                    <measurement group_id="O5" value="25.5" spread="3.74"/>
                    <measurement group_id="O6" value="12.8" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Seroconversion to Each of Four Dengue Serotypes</title>
        <description>Rate of seroconversion was defined as the percentage of participants with Plaque Reduction Neutralization Test titer resulting in 50 % reduction in Plagues (PRNT50) titer ≥ 10 for participants seronegative at Baseline or a greater than four-fold increase in PRNT50 for participants seropositive at Baseline.</description>
        <time_frame>Up to 30 days after the last immunization (Up to Day 120)</time_frame>
        <population>Participants from the Full Analysis Set, all enrolled participants, with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (D0:TDV,P D90:TDV)</title>
            <description>Takedas Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (D0:TDV,TDV D90:P)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
            <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
            <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
            <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (D0:1/10TDV D90:1/10TDV</title>
            <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Seroconversion to Each of Four Dengue Serotypes</title>
          <description>Rate of seroconversion was defined as the percentage of participants with Plaque Reduction Neutralization Test titer resulting in 50 % reduction in Plagues (PRNT50) titer ≥ 10 for participants seronegative at Baseline or a greater than four-fold increase in PRNT50 for participants seropositive at Baseline.</description>
          <population>Participants from the Full Analysis Set, all enrolled participants, with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue-1 Day 30 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.8"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="81.0"/>
                    <measurement group_id="O5" value="89.5"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-2 Day 30 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-3 Day 30 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="94.7"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-4 Day 30 (n=25, 24, 24, 21, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="81.0"/>
                    <measurement group_id="O5" value="57.9"/>
                    <measurement group_id="O6" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-1 Day 90 (n=25, 24, 23, 20, 18, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="95.7"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="72.2"/>
                    <measurement group_id="O6" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-2 Day 90 (n=25, 24, 23, 20, 18, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-3 Day 90 (n=25, 24, 23, 20, 18, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="82.6"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O6" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-4 Day 90 (n=25, 24, 23, 20, 18, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="38.9"/>
                    <measurement group_id="O6" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-1 Day 120 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.8"/>
                    <measurement group_id="O3" value="95.7"/>
                    <measurement group_id="O4" value="84.2"/>
                    <measurement group_id="O5" value="94.1"/>
                    <measurement group_id="O6" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-2 Day 120 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-3 Day 120 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.8"/>
                    <measurement group_id="O3" value="91.3"/>
                    <measurement group_id="O4" value="94.7"/>
                    <measurement group_id="O5" value="94.1"/>
                    <measurement group_id="O6" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue-4 Day 120 (n=25, 24, 23, 19, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="52.2"/>
                    <measurement group_id="O4" value="73.7"/>
                    <measurement group_id="O5" value="76.5"/>
                    <measurement group_id="O6" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 120</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (D0:TDV,P D90:TDV)</title>
          <description>Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and TDV placebo (P), 0.5 mL, subcutaneous injection in the other arm on Day 0 (D0). TDV, 0.5 mL, subcutaneous injection on Day 90 (D90).</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (D0:TDV,TDV D90:P)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV placebo, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (D0:TDV,TDV D90:TDV)</title>
          <description>TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.</description>
        </group>
        <group group_id="E4">
          <title>Group 4 (D0:TDVN,P D90:TDVN,P)</title>
          <description>TDV new formulation (TDVN), 0.5 mL, subcutaneous injection in one arm and TDV new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="E5">
          <title>Group 5 (D0:TDVN,TDVN D90:TDVN,TDVN)</title>
          <description>TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.</description>
        </group>
        <group group_id="E6">
          <title>Group 6 (D0:1/10TDV D90:1/10TDV)</title>
          <description>1/10 TDV, 0.5 mL, subcutaneous injection on Days 0 and 90.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

